Akèy › Kansè nan tete › Virginia › Arlington
Etid klinik pou Kansè nan tete nan Arlington, VA
47 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology - Virginia, Fairfax · 11 mi lwen
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ap rekriteFaz 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Ap rekriteFaz 2
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Ap rekriteFaz 3
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi lwen
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 11 mi lwen
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Fairfax · 11 mi lwen
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Inova, Fairfax · 11 mi lwen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Ap rekriteFaz 1
- Next Virginia, Fairfax · 11 mi lwen
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- NEXT Oncology, Fairfax · 11 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Fairfax · 11 mi lwen
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Ap rekriteFaz 1/2
- Next Oncology, Fairfax · 11 mi lwen
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · 11 mi lwen
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi lwen
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer Institute, Falls Church · 4 mi lwen
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Inova Fairfax Hospital, Falls Church · 4 mi lwen
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- ak 1 plis
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Ap rekriteFaz 3
- INOVA Schar Cancer, Fairfax · 11 mi lwen
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- NEXT, Fairfax · 11 mi lwen
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Ap rekriteFaz 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 11 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Virginia Cancer Specialists, PC, Reston · 14 mi lwen
- Virginia Cancer Specialists, Manassas · 22 mi lwen
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- NEXT, Virginia, Fairfax · 11 mi lwen
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- Inova Schar Cancer Center, Fairfax · 11 mi lwen
- NEXT Virginia, Fairfax · 11 mi lwen
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Ap rekriteFaz 1
- Biotheryx Investigative Site, Fairfax · 11 mi lwen
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Arlington
- Kansè Poumon ki pa ti selil104 etid
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè ovè46 etid
- Kansè poumon41 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè lestomak20 etid
- Kansè tete negatif triple20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.